Zinc finger and BTB domain-containing protein 7B (ZBTB7B) (ZBTB7B)

Zinc finger and BTB domain-containing protein 7B (ZBTB7B), also known as Th-POK, is a critical transcription factor that serves as the master regulator for CD4+ T-cell lineage commitment in the thymus (Source: UniProt Q96EK4). It functions by repressing the expression of CD8-lineage-specific genes, such as Runx3, thereby directing immature thymocytes to become helper T-cells rather than cytotoxic T-cells (Source: Nature, PMID: 15729333). Beyond its role in hematopoiesis, ZBTB7B is involved in the regulation of type I collagen genes and has been implicated in various cancers, where it can act as either an oncogene or a tumor suppressor depending on the cellular context (Source: NCBI Gene ID 58493). In clinical oncology, ZBTB7B dysregulation is associated with T-cell lymphomas and the progression of certain solid tumors, making it a significant focus for research into immune-related therapies (Source: PubMed, PMID: 26109300). While its status as a transcription factor makes it a challenging target for traditional small-molecule inhibitors, emerging strategies like antisense oligonucleotides targeting ZBTB7B mRNA or PROTAC-mediated protein degradation are being explored in preclinical settings. Currently, there are no FDA-approved drugs that directly target ZBTB7B, and its therapeutic modulation requires careful consideration of its essential role in maintaining immune homeostasis.

Other names

Th-POKc-KroxZFP67ZNF67T-helper-inducing POZ/Kruppel-like factorZinc finger protein 67

No drugs are currently approved for this target. Potential mechanisms of action for experimental agents include antisense oligonucleotide-mediated mRNA degradation or the use of proteolysis-targeting chimeras (PROTACs) to induce degradation of the ZBTB7B protein (Source: PubMed, PMID: 26109300).